Interleukin-6 Receptor Inhibition for Symptomatic Intracranial Atherosclerosis
Status:
NOT_YET_RECRUITING
Trial end date:
2029-06-30
Target enrollment:
Participant gender:
Summary
IRIS-sICAS is a multicenter, randomized, double-blind, placebo-controlled clinical trialis a multicenter, randomized, double-blind, placebo-controlled clinical trial, to assess the safety and efficacy of tocilizumab injection in lowering the incidence of newly diagnosis ischemic stroke and improving prognosis in symptomatic intracranial atherosclerosis patients.
Phase:
PHASE3
Details
Lead Sponsor:
Zhujiang Hospital
Collaborators:
Central People's Hospital of Zhanjiang Eighth Affiliated Hospital, Sun Yat-sen University Guangdong Provincial People's Hospital Guangzhou First People's Hospital Peking University Shenzhen Hospital Shantou Central Hospital Shenzhen Second People's Hospital